Yes, declining, but the rate of decline is improving and needs to be seen in the context of the FDA schmozzle. The FDA initiated a fullon review into TST as there was a big question on whether axiron contributed to the death of middle aged people taking it and whether it would be banned or not. In that environment ACR went from poster boy to leper and the viability of the company was rightfully questioned.
This set of results helps to contribute to the belief in the ongoing viability of ACR and their likelihood of paying steady dividends, rather than last year's being a one off.
Hope that helps to put Q1 16 in context.
Wazz
ACR Price at posting:
67.5¢ Sentiment: Buy Disclosure: Held
